A booster shot of the Pfizer-BioNTech vaccine appeared to increase the immune response against coronavirus in children aged 5 through 11, providing significant protection against both the original COVID-19 strain and the Omicron variant, the companies said in a press release Thursday.
Pfizer and BioNTech’s trial was announced in December and it included 140 children who were administered a booster shot six months after their second dose, the release said.
The pharmaceutical companies said that they will request authorization from the Food and Drug Administration, and if the FDA approves the booster for children aged 5–11, the government could extend the eligibility for booster shots which would include 28 million more children, The Washington Post reports.
